Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Autor: Dekhtiarenko, Iryna *, Lelios, Iva *, Attig, Jan *, Sleiman, Nassim *, Lazzaro, Domenico *, Schindler, Emilie *, Eckmann, Jan *, Umana, Pablo, Jacob, Wolfgang *, Schneider, Meike *, Carlo-Stella, Carmelo, Mazza, Rita *, Manier, Salomon, Facon, Thierry *, Yoon, Sung-Soo, Koh, Youngil *, Harrison, Simon J, Er, Jeremy *, Pinto, Antonio *, Volzone, Francesco *, Perrone, Giulia *, Corradini, Paolo, Cazaubiel, Titouan *, Hulin, Cyrille *, Touzeau, Cyrille *, Moreau, Philippe *, Ocio, Enrique M., Montes Gaisan, Carmen Maria *, Popat, Rakesh *, Leong, Sarah *, Offner, Fritz, Rodriguez Otero, Paula *, Alfonso-Pierola, Ana *, Hutchings, Martin *, Riley, Caroline Hasselbalch *, Bröske, Ann-Marie E *
Zdroj: In Blood 15 November 2022 140 Supplement 1:10137-10139
Databáze: ScienceDirect